BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suzuki R, Kitamura Y, Nakamura Y, Akashi H, Ogawa Y, Kawada H, Ando K. Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma. Oncotarget 2020;11:3984-97. [PMID: 33216827 DOI: 10.18632/oncotarget.27775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Vendramini E, Bomben R, Pozzo F, Bittolo T, Tissino E, Gattei V, Zucchetto A. KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders. Cancers (Basel) 2022;14:666. [PMID: 35158933 DOI: 10.3390/cancers14030666] [Reference Citation Analysis]
2 Suzuki R, Kitamura Y, Ogiya D, Ogawa Y, Kawada H, Ando K. Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma. Int J Hematol 2021. [PMID: 34741230 DOI: 10.1007/s12185-021-03244-1] [Reference Citation Analysis]
3 Tatli O, Dinler Doganay G. Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy. Molecules 2021;26:7561. [PMID: 34946644 DOI: 10.3390/molecules26247561] [Reference Citation Analysis]